Skip to main content

Preclinical Licensing Deal Benchmarks

Median Upfront
$32M
Range: $11M - $62M
Total Deal Value
$504M
Range: $202M - $806M
Royalty Rate
5.4% - 10.7%
Tiered up to 14.7%
Dev Milestones
$236M
Range: $96M - $372M
Model Your Deal

Market Analysis

Preclinical licensing deals represent the highest-risk, highest-potential segment of biopharma deal-making. Median total deal values for preclinical (IND-enabling) assets reach $504M, with modest upfront payments of $32M reflecting the significant clinical risk ahead. These deals are characterized by heavily milestone-weighted structures where the bulk of value is contingent on successful clinical progression.

Development milestones dominate preclinical deal structures at $236M, covering IND filing, Phase 1 start, Phase 2 start, and Phase 3 initiation. Regulatory milestones add $142M, while commercial milestones of $94M reward successful commercialization. The recommended 6/94 upfront/milestone split is standard for this stage.

Royalty rates for preclinical assets start at 5.4%-10.7%, the lower end of industry ranges, reflecting early clinical risk. Platform technology deals with multi-target potential often negotiate higher royalties in exchange for lower upfronts, while single-asset deals favor higher upfronts with lower royalty commitments.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical upfront payments for preclinical licensing deals?
Preclinical deal upfronts average $32M, ranging from $11M to $62M. The modest upfronts reflect the significant clinical risk and are balanced by substantial milestone potential as the asset progresses through development.
How are preclinical deal milestones structured?
Preclinical deals allocate approximately 94% of total value to milestones. Development milestones ($236M) represent the largest component, gating payments to IND filing, clinical phase starts, and pivotal trial initiation.
What makes a preclinical asset attractive for licensing?
Key factors include novel and validated target biology, strong IND-enabling preclinical data (efficacy, PK, safety), differentiated mechanism of action, clear competitive advantages, strong IP position, and a defined regulatory pathway. Platform technologies with multi-indication potential also attract premium interest.
How do preclinical deal terms vary by modality?
Preclinical deal terms vary significantly by modality. Cell and gene therapies, ADCs, and radiopharmaceuticals command higher total deal values due to platform complexity and manufacturing barriers. Small molecules and naked antibodies are valued more conservatively at the preclinical stage.

Related Benchmarks

Phase 2 Deal Benchmarks

View

Gene Therapy Deals

View

Small Molecule Deals

View

Oncology Deal Overview 2026

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating